Cliffside Labs L.L.C.

Cliffside Labs L.L.C. was paid $325K by Medicaid between Jan 2018 and Mar 2024, across 37 billing codes. Its largest line is 80307, Drug test(s), presumptive, any number of drug classes; immunoassay — 31% of everything it billed.

33Billing provider infoCLIFFSIDE LABS L.L.C.
MONMOUTH, NJ 08852

33aNPI1518366426assigned 08/15/2014

33bProvider typeClinical Medical Laboratory

28Total paid$325K

24GClaims6,369

24DCodes billed37

24AFirst – last monthJan 2018 – Mar 2024

Compared with peers

Next to other Clinical Medical Laboratory providers in New Jersey

Rank by total paid#77 of 122

Median peer was paid$1.29M

This provider vs. median0.3×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	1,126	$101K
2019	304	$19K
2020	1,321	$101K
2021	957	$79K
2022	767	$8K
2023	1,500	$7K
2024incomplete	394	$10K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	31%	2,474	2,045	$99K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	23%	699	550	$75K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	15%	608	570	$49K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	14%	491	405	$44K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	9.6%	284	228	$31K
81307		1.1%	44	41	$3K
82542		1.0%	157	128	$3K
81404		<1%	69	58	$3K
81406		<1%	59	58	$2K
81405		<1%	56	55	$2K
81302		<1%	174	163	$2K
81321		<1%	45	41	$2K

25 more codes

81403		<1%	72	$1K
81238		<1%	79	$1K
81223		<1%	77	$1K
81249		<1%	51	$1K
81351		<1%	22	$1K
81317		<1%	31	$580.97
81311		<1%	77	$555.02
81320		<1%	25	$554.78
81334		<1%	30	$297.91
81256		<1%	77	$290.03
81298		<1%	31	$259.59
81479	Unlisted molecular pathology procedure	<1%	274	$256.66
81339		<1%	15	$167.44
81345		<1%	78	$167.44
81279		<1%	15	$167.44
81216		<1%	13	$167.39
81305		<1%	13	$158.58
81250		<1%	15	$52.88
81330		<1%	47	$47.00
81332		<1%	47	$43.65
81241		0%	12	$0.00
81185		0%	23	$0.00
81242		0%	31	$0.00
81209		0%	31	$0.00
81189		0%	23	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialDUNNE, LIAM (AUTHORIZED OFFICIAL)